A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

NCT02079532 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

302

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: rituximab [MabThera]

Sponsor

Hoffmann-La Roche